ZyCoV-D
Sign in to saveKey facts
- Drug.type
- vaccine
- Drug.image
- ZyCoV-D Logo.svg
- Drug.target
- SARS-CoV-2
- Drug.vaccine_type
- DNA
- Drug.routes_of_administration
- Intradermal
- Drug.ATC_prefix
- None
- Drug.legal_status
- Full list of ZyCoV-D authorizations
- Drug.CAS_number
- 2541524-47-2
- Drug.DrugBank
- DB15892
via Wikipedia infobox
Article
11 sectionsContents
- Technology
- Clinical trials
- Pre-clinical trials
- Phase I and II trials
- Phase III trials
- Authorizations
- Deployment
- See also
- References
- Further reading
- External links
ZyCoV-D is a DNA plasmid-based COVID-19 vaccine developed by Indian pharmaceutical company Cadila Healthcare, with support from the Biotechnology Industry Research Assistance Council. It is approved for emergency use in India.
== Technology == The vaccine contains a DNA plasmid vector that carries the gene encoding the spike protein of SARS-CoV-2. As with other DNA vaccines, the recipient's cells then produce the spike protein, eliciting a protective immune response. The plasmid also contains unmethylated CpG motifs to enhance its immunostimulatory properties.